Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Switching patients from stable PI-based, NNRTI-based, or elvitegravir/cobicistat-based regimens to doravirine/lamivudine/tenofovir DF found to be noninferior at Week 48 primary endpoint analysis to continuing baseline ART in the DRIVE-SHIFT trial[Johnson 2019]
- In patients receiving baseline PI-based ART, switch to doravirine/lamivudine/tenofovir DF significantly reduced low density lipoprotein cholesterol and non–high density lipoprotein cholesterol vs continuing PI/ritonavir-based ART
- At Week 144, (end of the extension phase), 80.1% of those in the immediate switch group and 83.7% of those in the delayed switch group maintained HIV-1 RNA < 50 copies/mL by FDA snapshot analysis[Kumar 2021]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content